4 assets in Plasmacytoma

Therapeutic assets addressing Plasmacytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dexasone Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	B (63)
Lenalidomide Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Azacitidine Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Bcma-Cart Cells Plasmacytoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (48)